ClinicalTrials.gg
RecruitingNCT04309487Updated May 18, 2026

Diagnostic Accuracy of ShuntCheck Compared to Radionuclide Shunt: Patency in Patients With Normal Pressure Hydrocephalus

An observational study in Hydrocephalus, Normal Pressure, sponsored by University of South Florida. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by University of South Florida · Observational

How we know

From the registry’s dates

  • Started Jan 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
20
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Hydrocephalus, Normal Pressure with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Hydrocephalus, Normal Pressure · United States.

Started
2020
with 1 other
Observational
9 of 24
2 open now
Registered
19th of 24
by date
Lead sponsor
2 of 24
University of South Florida

Among the 24 studies in Hydrocephalus, Normal Pressure with a site in United States, this one is one of 2 that started in 2020, is one of 9 observational ones, and was the 19th registered.

Hydrocephalus, Normal Pressure

78 studies on the registry are indexed under Hydrocephalus, Normal Pressure; 20 are open to participants now.

Browse Hydrocephalus, Normal Pressure studies →

Open to participants now

4 of the 24 studies in Hydrocephalus, Normal Pressure with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Hydrocephalus, Normal Pressure studies recruiting now, 12 (75%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 40 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hydrocephalus, Normal Pressure with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the diagnostic accuracy of ShuntCheck compared with radionuclide shunt patency testing (SPS) to detect CSF shunt flow of NPH patients with suspected shunt obstruction.

Read the detailed description

The purpose of this study is to assess the diagnostic accuracy of ShuntCheck compared with radionuclide shunt patency testing (SPS) to detect CSF shunt flow of NPH patients with suspected shunt obstruction.

03

Conditions studied

  • Hydrocephalus, Normal Pressure

Keywords

  • Asymptomatic Normal Pressure Hydrocephalus
  • Ventriculoperitoneal Shunt
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

The study population will consist of NPH hydrocephalus research subjects who have a VP shunt with a single ventricular catheter implanted for adult hydrocephalus are suspected of shunt obstruction and are scheduled for a radionuclide SPS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women 40 yo or older and have a VP shunt placed for NPH and are suspected of shunt obstruction.
  • Capable of providing valid signed , or has a legal guardian, health care agent, or surrogate decision maker (according to local statutes, and collectively referred to as "surrogates" in this protocol) capable of providing valid, signed informed consent

Exclusion criteria

Exclusion Criteria:

  • Presence of multiple shunts, or presence of more than one distal shunt catheter (regardless of function) crossing the clavicle ipsilateral to the shunt with suspected obstruction;
  • ShuntCheck test would interfere with standard patient care, or emergency shunt surgery that cannot be delayed is indicated;
  • Presence of an interfering open wound or edema over any portion of the VP shunt.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • ShuntCheck

    Participants will be administered the ShuntCheck diagnostic test.

    Diagnostic Test: ShuntCheck

Interventions

  • Diagnostic testShuntCheck

    The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.

06

What researchers measure

Primary outcomes

  1. Sensitivity of ShuntCheck compared to radionuclide shunt patency study

    Time frame: 15 minutes

  2. Negative Predictive Value of ShuntCheck compared to radionuclide shunt patency study

    Time frame: 60 Minutes

07

Study locations

1 of 1 sites recruiting
  • University of South Florida Department of Neurological Surgery and Brain Repair
    Tampa, Florida 33606, United States
    Recruiting
    • Naomi Abel, MD · Contactnabel@usf.edu · 813 259-0904
    • Konrad Bach, MD · Contactkbach@usf.edu · 813 259-8898
    • Naomi Abel, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — At present there is no plan to share any individual participant data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2020 (actual). Primary completion is estimated for Jan 2027, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2020
First posted
Mar 16, 2020
StartActual
Jan 24, 2020
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04309487
Collaborators
NeuroDx Development
Responsible party
Naomi Abel (Assistant Professor, College of Medicine Neurosurgery, University of South Florida) — Principal investigator
First posted
Mar 16, 2020
Start date
Jan 24, 2020
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
May 18, 2026

Study contacts

Naomi Abel, MD
Contact
nabel@usf.edu
813 259-0904
Thanh Tran, MD
Contact
tqtran@usf.edu
813 8448544
Naomi Abel, MD
principal investigator · University of South Florida

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion